Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) (TRIVERSYTI)

第3相完了 NCT03197818

対象疾患	COPD
相	第3相
スポンサー	Chiesi Farmaceutici S.p.A.
ステータス	完了
参加者数	708 名
介入（薬剤）	CHF 5993 100/6/12.5 µg, 160 µg budesonide + 4.5 µg formoterol fumarate
開始日	2016年12月14日
完了日	2020年5月26日
結果公開日	2026年5月27日

概要

Primary Objective • To demonstrate the superiority of CHF 5993 pressurised metered dose inhaler (pMDI) over Symbicort® Turbuhaler® in terms of pulmonary function (change from baseline in pre-dose morning forced expiratory volume in the first second of a forced vital capacity manoeuvre \[FEV1\] and 2-hour post-dose morning FEV1 at Week 24). Secondary Objectives Key secondary objective: • To demonstrate the superiority of CHF 5993 pMDI over Symbicort® Turbuhaler® in terms of pulmonary function (change from baseline in pre-dose morning FEV1 and 2-hour post-dose morning FEV1 at Week 24) in the subgroup of Chinese population. Other secondary objectives: * To evaluate the effect of CHF 5993 pMDI on other lung function parameters, patient's health status and clinical outcome measures; * To collect data in order to assess the impact of study treatments on health economic outcomes; * To assess the safety and the tolerability of the study treatments.

Change From Baseline in Pre-dose Forced Expiratory Volume Within the First Second (FEV1) at Week 24

Week 24 (Visit 6) · Liters

CHF 5993 100/6/12.5 µg - ITT Population	0.030 Liters
Symbicort Turbuhaler 160/4.5 µg - ITT Population	-0.032 Liters

p-value	< 0.001
adjusted mean difference	0.062 (95% CI 0.038–0.085)

Change From Baseline in 2-hour Post-dose FEV1 at Week 24

Week 24 (Visit 6) · Liters

CHF 5993 100/6/12.5 µg - ITT Population	0.185 Liters
Symbicort Turbuhaler 160/4.5 µg - ITT Population	0.072 Liters

p-value	< 0.001
adjusted mean difference	0.113 (95% CI 0.087–0.140)

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and — University of Tennessee Graduate School of Medicine
Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster — Chiesi Farmaceutici S.p.A.
Tiotropium/Salmeterol Inhalation Powder in COPD — Boehringer Ingelheim
Risk Factors, Costs, and Impacts of ED Boarding — University of Maryland, Baltimore
Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructiv — United Therapeutics
Anti-Platelets in Chronic Obstructive Pulmonary Disease — Brigham and Women's Hospital

すべての治験

このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。

English 한국어 日本語中文 Русский